



Tuesday, 1 February 2022

## DISCONTINUANCE OF CLASS ACTION AGAINST API

Australian Pharmaceutical Industries (ASX:API) today advised that it had received correspondence from the claimants' legal representatives that they will seek the Court's leave to discontinue the class action filed against API and Priceline in Victoria's Supreme Court.

API intended to vigorously defend the action but is pleased that the claims against it will be withdrawn subject to Court approval in the coming weeks.

API remains focussed on supporting Priceline Pharmacy franchisees through the current phase of the COVID-19 pandemic as they serve their communities.

Announcement authorised by the CEO & Managing Director of API.

---

### For further information:

#### Investors

Carolyn Ireland  
API  
T: +61 403 045 905

#### Media

James Tait  
Res Publica  
T: +61 400 304 147

